Chipiron

Executive Summary

Chipiron is a Paris-based startup founded in 2019 with a mission to democratize MRI technology and ultimately end cancer through early detection. The company is developing the first light, inexpensive, and open full-body MRI machine that does not compromise image quality. By making MRI accessible and affordable, Chipiron aims to enable widespread screening and monitoring of cancer and other diseases, potentially transforming diagnostic imaging. The company operates at the intersection of AI, drug delivery, and digital health, leveraging advanced machine learning to enhance imaging capabilities and reduce costs. While still in the development stage and lacking disclosed funding or valuation, Chipiron's innovative approach addresses a critical gap in healthcare—providing high-quality imaging in a scalable, low-cost format. The startup's technology has the potential to disrupt the traditional MRI market, which is dominated by heavy, expensive machines. Given the early stage, risks include technical feasibility, regulatory hurdles, and market adoption, but the bold vision and experienced team (headquartered in Paris tech hub) position Chipiron as a compelling long-term opportunity in healthtech.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round75% success
• Q2 2027First Prototype Demonstration50% success